At RemainBrain Biosciences, we are developing a new class of small molecule therapeutics for the treatment of neurodegenerative diseases, specifically Alzheimer's disease (AD). Our lead compound, RB-x03-9, defend healthy brain tissue by inhibiting neuro-inflammation and prevention of plaque formation.
Besides amyloid ß plaque and Tangle formation, one of the hallmarks of AD is the low-grade chronic inflammation of brain tissue, which not only contributes to but also accelerates the pathological process.
RB-X03-9 is an orally available inhibitor of NRLP-3 inflammasomes an and inducer of autophagy. NRLP-3 plays a critical role in neuro-inflammation and its inhibition almost completely inhibits the secretion of the pro-inflammatory cytokines IL-1ß and IL-18. Stimulation of autophagy results in enhanced clearing of amyloid ß. Pre-clinicaly proof of concept has been obtained in AD mice who received RB-X03-9 orally for 12 weeks, which rescued cognitive decline and led to a >80% reduction in plaque formation as compared to non-AD wild typ mice and sham treated AD mice.
2312 JW Leiden
+316 18 51 60 8